Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
AJG vs MDT: Weighing an Insurance Brokerage Against a Medical Technology Leader

AJG vs MDT: Weighing an Insurance Brokerage Against a Medical Technology Leader

Key Takeaways

  • AJG is a diversified insurance brokerage and risk management leader benefiting from aggressive acquisition growth, while MDT is a global medical technology company riding momentum in cardiovascular and ablation products.
  • Tickeron AI Verdict: Based on trend consistency, earnings momentum, and clearer catalysts, MDT is the ticker of choice in this comparison.
  • MDT has outperformed both the S&P 500 and the broader medical devices sector over the past year, while AJG has delivered strong headline earnings but faced a slight consensus miss and analyst caution.
  • MDT offers a higher dividend yield and a decades-long payout-growth streak, whereas AJG trades at a lower beta and a defensive, recurring-revenue business profile.
  • Get more details on AJG Major News and AJG Today's Price Move, as well as MDT Major News and MDT Today's Price Move, to track the latest developments.
  • For AI-driven market insight, explore Trending AI Robots to see which automated strategies are currently favored.

Introduction

Investors comparing AJG (Arthur J. Gallagher & Co.) and MDT (Medtronic plc) are weighing two very different business models. One is a defensive, acquisition-driven insurance brokerage and risk management firm; the other is a large-cap medical technology company with a broad product pipeline. This stock comparison is relevant to investors and traders evaluating relative performance, market positioning, and momentum across the financial services and healthcare sectors. Both names have generated meaningful headlines in recent weeks, making a side-by-side review of their fundamentals, catalysts, and sentiment timely for those building watchlists or rebalancing diversified portfolios. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in their industries.

AJG Overview and Recent Performance

AJG is a global insurance brokerage and risk management company operating through its Brokerage and Risk Management (Gallagher Bassett) segments. Its growth strategy leans heavily on acquisitions, having completed dozens of deals in recent periods, including the large AssuredPartners integration. In its most recent quarter, AJG reported total revenue before reimbursements of roughly $3.93 billion, up about 18% year over year, with combined Brokerage and Risk Management organic growth of 5%. Adjusted EBITDAC grew about 25%, marking a long streak of double-digit expansion.

Despite the strong headline results, sentiment has been mixed. Reported earnings per share and revenue came in slightly below consensus expectations, and one major bank downgraded the stock to a neutral rating in recent weeks, citing a more balanced risk-reward profile. The shares carry a low beta, reflecting their defensive character, but have lagged the broader market over the trailing twelve months. Ongoing themes include margin expansion, acquisition synergies, and a substantial capital capacity for future deals.

MDT Overview and Recent Performance

MDT is a global healthcare technology company spanning cardiovascular, neuroscience, medical surgical, and formerly diabetes care. A defining recent development was the completion of the spin-off of its diabetes business (now MiniMed), which retired a large block of shares and sharpened the company's strategic focus. In its latest reported quarter, MDT delivered adjusted earnings per share growth of about 15% and revenue growth of roughly 14%, beating consensus, and it raised its fiscal-year organic revenue growth outlook.

Momentum has been supported by strength in electrophysiology and cardiac ablation products, positive real-world data from its renal denervation program, and an FDA label update. At least one major firm upgraded the stock in recent weeks, reflecting greater confidence in growth durability. Over the past year, MDT has outperformed both the S&P 500 and the broader medical devices exchange-traded fund, supported by a dividend yield above the market average and a payout growth streak spanning nearly five decades. From what I see, the product catalysts here look particularly durable right now.

Head-to-Head Comparison

The clearest contrast between these two names is sector exposure and earnings character. AJG is a financial-services company with recurring, fee-based revenue and a low-volatility profile, but its growth is partly dependent on acquisition execution and integration risk. MDT is a cyclical-healthcare product company whose growth hinges on product innovation, regulatory approvals, and procedure volumes. In terms of momentum, MDT has shown stronger relative performance and more consistent earnings beats, while AJG faces near-term analyst caution despite solid margins. Valuation also diverges: AJG trades at a higher trailing price-to-earnings multiple offset by a lower forward multiple, whereas MDT offers a comparatively moderate multiple and a more substantial dividend yield. Risk profiles differ accordingly, with AJG more defensive and MDT more growth-catalyst dependent.

Tickeron AI Verdict

On observable factors, Tickeron's AI would currently favor MDT. The medical technology company has demonstrated stronger trend consistency, a pattern of beating earnings expectations, an upwardly revised growth outlook, and multiple product catalysts, all of which support a more favorable momentum profile. By contrast, AJG presents a resilient but comparatively mixed near-term picture, with a slight consensus miss and analyst downgrade tempering its otherwise strong fundamentals. While AJG remains a quality defensive franchise, the current balance of catalysts, relative performance, and market positioning tilts the probabilistic assessment toward MDT. I’m watching this closely as earnings season progresses.

Using AI Tools for Deeper Research

In my own analysis, I often turn to Tickeron’s AI Trading Bots to test how automated strategies might align with names like these. The platform hosts hundreds of bots across thousands of tickers, letting users review performance statistics, trading styles, and timeframes before deciding what fits their outlook. It’s a practical way to add another layer of data-driven perspective without replacing fundamental work.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MDT, AJG

Momentum Indicator for MDT turns positive, indicating new upward trend

MDT saw its Momentum Indicator move above the 0 level on October 12, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 47 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 55%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for MDT just turned positive on October 12, 2026. Looking at past instances where MDT's MACD turned positive, the stock continued to rise in 23 of 42 cases over the following month. The odds of a continued upward trend are 55%.

MDT moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MDT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 47%.

Following a +3.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDT advanced for three days, in 171 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.

The Aroon Indicator entered an Uptrend today. In 87 of 237 cases where MDT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 37%.

Bearish Trend Analysis

The 10-day RSI Indicator for MDT moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 12 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 46%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 67 cases where MDT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 51%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.

MDT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 17 (best 1 - 100 worst), indicating outstanding price growth. MDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.592) is normal, around the industry mean (4.142). P/E Ratio (24.890) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.608) is also within normal values, averaging (11.253). Dividend Yield (0.028) settles around the average of (0.011) among similar stocks. P/S Ratio (3.176) is also within normal values, averaging (40.124).

The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was 1%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -6%. POAS experienced the highest price growth at 351%, while NPCE experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 28%. For the same stocks of the Industry, the average monthly volume growth was 24% and the average quarterly volume growth was 13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 60
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 13 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of medical technology services

Industry MedicalNursingServices

Industry
Medical Specialties
Address
Parkmore Business Park West
Phone
+353 14381700
Employees
95000
Web
https://www.medtronic.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
LITE is the Nasdaq-listed ticker for Lumentum Holdings Inc., a global manufacturer of optical and photonic products used in data centers, AI infrastructure, and telecommunications networks. The company was spun off from JDS Uniphase and incorporated in 2015, with headquarters in San Jose, California.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.
SNDK is the NASDAQ ticker for SanDisk Corporation, a global developer and manufacturer of data storage products built on NAND flash memory technology. SanDisk is one of the world's largest suppliers of NAND flash semiconductors, offering solid-state drives (SSDs), embedded storage, removable memory cards, and USB flash drives.
QCOM is the ticker for Qualcomm Incorporated, a U.S.-based semiconductor and wireless technology company headquartered in San Diego, California. Qualcomm designs advanced chips and licenses foundational wireless patents, operating through two main segments: QCT (semiconductors) and QTL (technology licensing).